Clinical Trial

Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
View on ClinicalTrials.gov →
Summary
This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-16.
Trial Details
NCT Number NCT07483385
Lead Sponsor The General Hospital of Western Theater Command
Conditions Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation, Hematologic Disorders
Enrollment 45 participants
Start Date 2026-01-13
Primary Completion 2027-01-28 (estimated)
Study Completion 2028-01-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-25